Logo

Biodesix: Kieran O'Kane, Bobbi Coffin

Mar 10, 2020

Biodesix has announced a realignment of its commercial executive team. Effective immediately, current head of strategic marketing Kieran O'Kane will become the company's chief commercial officer, while Bobbi Coffin, currently chief marketing officer, will become the firm's chief growth officer.

After joining the company in 2018, Biodesix said that O'Kane played a leading role in the successful acquisition of Integrated Diagnostics and Oncimmune's laboratory and incidental pulmonology nodule malignancy test, proving instrumental in the subsequent commercial launch of what are now the Nodify XL2 and Nodify CDT tests. He previously worked at various other companies, including NanoString Technologies, Bristol Myers Squibb, and Roche.

Coffin joined Biodesix in 2015 from Exact Sciences where she was VP of commercial marketing and strategy. Prior to that role, she held leadership positions at Precision Therapeutics and Cytyc/Hologic.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.